A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs AMG-424 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 26 Nov 2019 Planned End Date changed from 28 Dec 2022 to 1 Mar 2023.
- 26 Nov 2019 Planned primary completion date changed from 28 Dec 2022 to 1 Mar 2023.
- 26 Nov 2019 Status changed from active, no longer recruiting to recruiting.